Brief Summary
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Protocol Interventions
Drug: Rituximab, Drug: Methotrexate, Drug: Procarbazine, Drug: Temozolomide, Biological: Liso-cel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Calcium folinate